Sol-Gel Signs Six Exclusive License Deals for TWYNEO® and EPSOLAY® in Europe and South Africa

Sol-Gel Technologies, Ltd., a dermatology company known for innovative treatments for severe skin conditions, has announced the signing of six exclusive licensing agreements to commercialize their dermatology products, TWYNEO® and EPSOLAY®, across a broad spectrum of European countries. The agreements are with MagnaPharm Trading Slovakia S.R.L, Galenica A.B, Leman SKL SA, InfectoPharm, Aspire Pharma Limited, and Abex Pharmaceutica (PTY) Ltd. The covered countries include Germany, the United Kingdom, France, Poland, and several others, extending to South Africa.

Under these agreements, Sol-Gel is set to receive significant financial benefits, including upfront payments and regulatory milestone payments totaling up to a low seven-digit USD amount. Additionally, they will earn either a fixed transfer sale price or low double-digit royalties from net sales, supported by commitments to minimum annual sales. The responsibility for regulatory submissions in the various territories will fall to Sol-Gel’s partners, although Sol-Gel will assist with the preparation of these submissions.

These new collaborations build on Sol-Gel's existing agreements in the US, Canada, and China, highlighting the trust and commercial potential of their products. The Chief Executive Officer of Sol-Gel, Alon Seri-Levy, expressed pride in this achievement, indicating that it marks the successful execution of the company's goals to expand the availability of EPSOLAY and TWYNEO. He hinted at more agreements in the future as the company continues to strengthen its market position.

EPSOLAY® is a topical cream designed for adults to treat the inflammatory lesions associated with rosacea. Utilizing a proprietary technology, EPSOLAY encapsulates benzoyl peroxide (BPO) within silica-based microcapsules, creating a barrier between the medication and the skin. This allows for a controlled, slow release of BPO, enhancing the treatment's tolerability and effectiveness.

TWYNEO® is another topical cream developed by Sol-Gel, aimed at treating acne vulgaris in adults and children over nine years old. It contains a fixed-dose combination of tretinoin and benzoyl peroxide. These two ingredients are commonly prescribed individually for acne, but benzoyl peroxide can degrade tretinoin, reducing its effectiveness. TWYNEO uses a unique silica-based encapsulation technology to keep the two active ingredients separate within the cream, ensuring their stability and efficacy.

Sol-Gel Technologies continues to advance its pipeline with notable progress in the clinical development of other dermatological treatments. The company is conducting a Phase 3 clinical trial for SGT-610 (patidegib gel, 2%) aimed at Gorlin syndrome, a condition that leads to recurring skin cancers. Additionally, Sol-Gel is investigating SGT-210, a topical treatment for rare hyperkeratinization disorders.

In summary, Sol-Gel Technologies is making significant strides in expanding the reach of its dermatological products through strategic partnerships across Europe and South Africa. By securing these licensing agreements and continuing to innovate, the company is set to enhance its commercial footprint and address unmet needs in the treatment of complex skin conditions.